Sunday, March 17, 2019, Honolulu, Hawaii, 11:00 AM – 12:30 PM

Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

10:30 AM – 11:00 AM — Registration
11:00 AM – 12:30 PM — Educational Lunch Meeting

Meeting Room:
Kalakaua Ballroom A (Level 4)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Robert L Coleman, MD
Professor and Executive Director
Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Professor Jonathan A Ledermann
Professor of Medical Oncology
Clinical Director
University College London Cancer Institute
Director, Cancer Research UK and UCL Cancer Trials Centre
London, United Kingdom

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Amit M Oza, MD
Chief, Division of Medical Oncology and Hematology
Professor of Medicine, University of Toronto
Toronto, Canada

Neil Love, MD
Research To Practice
Miami, Florida
This CME symposium will focus on the discussion of challenging clinical situations commonly faced by community-based clinicians regarding the integration of PARP inhibition into the care of patients with ovarian cancer.

The program will follow a dynamic learning format designed to both improve knowledge and assist attendees in becoming more effective caregivers. Leading up to the event, Research To Practice, in collaboration with the invited faculty, will consult with a small group of practicing gynecologic oncologists who care for patients with ovarian cancer to identify clinical questions and/or ambiguous data sets for which they would like to receive expert advice and feedback. During each of the 4 modules at the live activity, one faculty member will deliver a brief presentation reviewing recent data sets, available guidelines and ongoing clinical trials that inform decision-making related to the issues identified during the planning sessions. After each didactic presentation, an extended moderated panel discussion will garner the perspectives of the other faculty members on these topics.

To maintain audience interest and relevance, clinician attendees will have the opportunity to participate in a premeeting survey using networked iPads® that will include general and case-based questions related to the discussion content. The results will be displayed throughout the event to foster additional conversation. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Moderator Dr Neil Love will incorporate select submissions to enrich the panel discussions and ensure that a variety of perspectives emerge.

A detailed agenda will be made available in the coming weeks.

Target Audience:
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these tests to guide long-term treatment planning, including clinical trial accrual.
  • Review emerging trial data evaluating the use of PARP inhibition as maintenance therapy for patients with previously untreated OC responding to standard platinum-based chemotherapy, and consider the research and nonresearch implications of these findings.
  • Assess available clinical trial data with and FDA indications for the various PARP inhibitors when used as maintenance therapy for recurrent, platinum-sensitive OC, and develop strategies to identify patients for whom this approach might be appropriate.
  • Identify patients with multiregimen-refractory OC who may be appropriate candidates for a PARP inhibitor, and safely integrate PARP inhibitors into nonresearch therapy.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Develop an understanding of the mechanisms of action, available data and possible clinical roles of other investigational PARP inhibitors in preparation for their potential introduction into clinical practice.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy or immunotherapy, and refer appropriate and interested patients for clinical trial participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.

Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

Meeting Room:
Kalakaua Ballroom A (Level 4)

The Hawaii Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.


This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.